Promising Outlook for OS Therapies: Buy Rating Backed by Positive FDA Meeting and Strategic Positioning
I'm PortAI, I can summarize articles.
Analyst Jason McCarthy of Maxim Group maintained a Buy rating on OS Therapies Incorporated with a price target of $6.00. The positive Type C meeting with the FDA supports potential accelerated approval for their osteosarcoma treatment. The OST-HER2 program holds multiple FDA designations, enhancing its review potential. The company plans to release biomarker data at the JPM Healthcare Conference. Lake Street also maintained a Buy rating with a $17.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments